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Purpose: These are the clinical experiences of Korean incidental prostate cancer 
patients detected by transurethral resection of the prostate according to initial treat-
ment: active surveillance (AS), radical prostatectomy (RP) and hormone therapy 
(HT). Materials and Methods: We retrospectively reviewed the records of 156 in-
cidental prostate cancer patients between 2001 and 2012. The clinicopathologic 
outcomes were reviewed and follow-up results were obtained. Results: Among 156 
patients, 97 (62.2%) had T1a and 59 (37.8%) had T1b. Forty-six (29.5%) received 
AS, 67 (42.9%) underwent RP, 34 (21.8%) received HT, 4 (2.6%) received radio-
therapy, and 5 (3.2%) chose watchful waiting. Of 46 patients on AS, prostate-spe-
cific antigen (PSA) progression occurred in 12 (26.1%) patients. Among them, 3 
patients refused treatment despite PSA progression. Five patients, who underwent 
RP as an intervention, all had organ-confined Gleason score ≤6 disease. In 67 pa-
tients who underwent RP, 50 (74.6%) patients had insignificant prostate cancer and 
8 (11.9%) patients showed unfavorable features. During follow-up, biochemical re-
currence occurred in 2 patients. Among 34 patients who received HT, 3 (8.8%) pa-
tients had PSA progression. Among 156 patients, 6 patients died due to other causes 
during follow-up. There were no patients who died due to prostate cancer. Conclu-
sion: The clinical outcomes of incidental prostate cancer were satisfactory regard-
less of the initial treatment. However, according to recent researches and guidelines, 
immediate definite therapy should be avoided without a careful assessment. We 
also believe that improved clinical staging is needed for these patients.
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INTRODUCTION
Recently, incidental prostate cancer was diagnosed in less than 5% of patients who 
undergo benign prostatic hyperplasia-related surgery.1-3 The sub-classification for 
incidental prostate cancer was established in the 4th TNM staging system in 1992. 
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status, the proportion of insignificant prostate cancer, the 
proportion of unfavorable disease, and biochemical recur-
rence (BCR) status. We defined insignificant prostate can-
cer as organ-confined Gleason ≤6 disease with a tumor vol-
ume of <0.5 cm3, and unfavorable disease as prostate 
cancer with ECE and/or SVI and/or a postoperative Glea-
son score of ≥8. BCR was defined as a sustained increase in 
serum total PSA level of ≥0.2 ng/mL. In the HT group, we 
collected information regarding PSA progression according 
to the type of hormone therapy. In this group, we defined 
PSA progression as a sustained increase in serum total PSA 
levels of  ≥0.4 ng/mL.
We compared the clinical and pathological characteristics 
of each group using the chi-square test for categorical vari-
ables and ANOVA for continuous variables. All statistical 
analyses were performed using SPSS version 18.0 (SPSS 




We identified 156 incidental prostate cancer patients at our 
institute. The baseline patient characteristics are shown in 
Table 1. In total, 97 (62.2%) patients were stage T1a and 59 
(37.8%) were T1b. The average PSA before TURP was 
This classification was the result of several studies that 
found that patients with incidental prostate cancer had dif-
ferent oncological outcomes according to the percentage of 
cancer in the resected prostate after transurethral resection 
of the prostate (TURP); this sub-classification is still ap-
plied in the present day.4,5 However, recent study reported 
that classification according to a volume threshold of 5% tu-
mor involvement is not an independent prognostic factor for 
prostate cancer prognosis.6 Another study reported that no re-
sidual tumor is present after radical prostatectomy (RP) in in-
cidental prostate cancer patients regardless of the incidental 
prostate cancer stage.7 Thus, there is still a controversy re-
garding which treatment is appropriate in cases of inciden-
tal detection of prostate cancer. 
In our institute, several incidental prostate cancer patients 
were followed up, and their different clinical results were 
analyzed according to the initial treatment modalities. Here, 
we present the clinical experiences of these patients and 
discuss which treatment was the most appropriate.
MATERIALS AND METHODS
　　　
We retrospectively reviewed the records of 156 patients who 
had prostate cancer, detected incidentally during TURP, be-
tween 2001 and 2012. We excluded patients with positive 
prostate biopsy in simultaneous TURP and prostate biopsy, 
even if there were prostate cancer chips in the TURP speci-
mens. Clinical stage was determined according to a volume 
threshold of 5% tumor involvement after TURP. We col-
lected clinical and pathological parameters, including age, 
prostate-specific antigen (PSA) before/after TURP, prostate 
volume, resected prostate volume after TURP, Gleason 
score at TURP, clinical stage, and the initial treatment type. 
We also collected overall survival data.
We stratified the patients into three groups according to 
their main initial treatment: active surveillance (AS), RP, or 
hormone therapy (HT). For the AS group, we collected in-
formation about the period of AS, PSA progression status, 
intervention status during follow-up, the reason for inter-
vention on AS, and the type of intervention. We defined 
PSA progression as a doubling of the serum total PSA level 
in comparison with the post-TURP PSA. In the case of the 
RP group, we collected information about the pathologic 
stage, postoperative Gleason score, extracapsular extension 
(ECE), seminal vesicle invasion (SVI), perineural invasion, 
lymphovascular invasion, tumor volume, surgical margin 
Table 1. Baseline Patient Characteristics
No. of patients 156
Age 69.5±6.4
Prostate volume 43.7±24.9
PSA before TURP 4.57±4.24
PSA after TURP 1.43±1.66
Resected prostate volume 13.4±11.9
Gleason score at TURP (%)
    2-5 47 (30.1)
    6 80 (51.3)
    7 22 (14.1)
    8-10 7 (4.5)
Clinical stage (%)
    cT1a 97 (62.2)
    cT1b 59 (37.8)
Initial treatment (%)
    Active surveillance 46 (29.5)
    Watchful waiting 5 (3.2)
    Radical prostatectomy 67 (42.9)
    Hormone therapy 34 (21.8)
    Radiotherapy 4 (2.6)
Mean follow-up period 40.0±26.5
PSA, prostate-specific antigen; TURP, transurethral resection of the pros-
tate.
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to initial treatment (Table 2). There were no statistical dif-
ferences between initial treatment and follow-up period, 
PSA before TURP, prostate volume, or resected prostate vol-
ume after TURP. However, the mean age of the RP group 
was younger than that of other groups (p<0.001). Gleason 
score at TURP and clinical stage were statistically different 
between the AS group and other groups (p=0.031 and p= 
0.037, respectively).
Active surveillance group
The clinical results of the patients who received AS are shown 
in Table 3. In the AS group, 27 (65.2%) patients continued 
in the AS program, 14 (23.9%) received interventions, and 1 
patients died from other causes. Twelve (26.1%) patients ex-
hibited PSA progression during AS. Among these, 3 pa-
tients refused to receive any treatment despite PSA progres-
sion and 9 patients received treatment for PSA progression. 
Finally, out of 14 patients who received intervention, 5 pa-
tients were treated because of patient preference, even 
though there was no evidence of disease progression. Among 
the patients who received intervention, 5 patients under-
went RP and 9 patients received HT. Among the patients 
who chose RP for intervention, 2 patients had insignificant 
prostate cancer and other 3 patients had organ-confined dis-
ease with a Gleason score of ≤6.
Radical prostatectomy group
The pathologic outcomes after RP are listed in Table 4. In 
total, 21 of 67 (31.3%) patients had no residual prostate 
cancer. The average tumor volume was 0.42±0.91 (range: 
4.57±4.24 ng/mL and 1.43±1.66 ng/mL after TURP. 
Among them, 46 (29.5%) patients received AS, 67 (42.9%) 
patients underwent RP, 34 (21.8%) received HT, 4 (2.6%) 
received radiotherapy (RT), and 5 (3.2%) chose watchful 
waiting (WW). Among those who chose WW, 2 patients 
were of advanced age and 3 patients had other pathologi-
cally proven malignancies. Four patients chose RT because 
they refused RP. Of these 156 incidental prostate cancer pa-
tients, 6 patients died of other causes during follow-up and 
there were no patients who died due to prostate cancer. 
We compared clinicopathologic characteristics according 
Table 2. Comparison of the Clinicopathological Outcomes of Patients with Incidental Prostate Cancer According to Treatment
AS group RP group HT group p value
No. of patients 46 67 34
Age 69.9±6.4 66.2±4.7 70.9±5.7 <0.001
Mean follow-up period      41±28.1   44.4±25.5   37.0±21.3 0.325
Prostate volume   42.1±22.3   42.3±22.1   50.3±33.6 0.305
PSA before TURP   4.07±2.89   4.52±3.67   4.20±4.00 0.783
PSA after TURP   1.42±1.31   1.55±1.49   1.15±2.36 0.598
Resected prostate volume   13.4±10.5   12.8±11.6   14.1±14.3 0.886
Gleason score at TURP (%) 0.031
    2-5 21 (45.7) 14 (20.9)   9 (26.5)
    6 23 (50.0) 38 (56.7) 17 (50.0)
    7 2 (4.3) 12 (17.9)   5 (14.7)
    8-10 0 (0.0) 3 (4.5) 3 (8.8)
Clinical stage (%) 0.037
    cT1a 36 (78.3) 37 (55.2) 19 (55.9)
    cT1b 10 (21.7) 30 (44.8) 15 (44.1)
AS, active surveillance; RP, radical prostatectomy; HT, hormone therapy; PSA, prostate-specific antigen; TURP, transurethral resection of the prostate.
Table 3. Clinical Results of Patients with Incidental Prostate 
Cancer Who Received Active Surveillance
No. of patients 46
Mean PSA at the last follow-up of AS 1.61±1.35
PSA progression during AS period 12
    cT1a   6
    cT1b   6
Result of AS program 
    Maintenance of AS 28
    Intervention 14
    Follow-up loss   4
    Death during follow-up   1
Reason for intervention 
    PSA progression   9
    Patients preference   5
Type of intervention
    RP   5
    HT   9
AS, active surveillance; RP, radical prostatectomy; HT, hormone therapy; 
PSA, prostate-specific antigen.
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early stages and at younger ages, before patients exhibit 
lower urinary tract symptoms. In the pre-PSA era, there was 
a greater possibility that incidental prostate cancer would be 
locally advanced prostate cancer rather than ‘true’ inciden-
tal prostate cancer, since early detection of prostate cancer 
by PSA screening was not available. In addition, consider-
ing the PSA prostate biopsy strategy, simultaneous TURP 
0-5.6). Fifty (74.6%) patients had insignificant prostate can-
cer. Among these, 30 patients were clinical stage T1a and 
20 patients were clinical stage T1b. Eight (11.9%) patients 
had unfavorable features. Among these, 3 patients were 
clinical stage T1a and 5 patients were clinical stage T1b. 
During follow-up, biochemical recurrence occurred in 2 pa-
tients. 
Hormone therapy group
Among the 34 patients who received HT, 9 (26.5%) patients 
received luteinizing hormone-releasing hormone agonists, 6 
(17.6%) patients received anti-androgen (AA) monotherapy, 
and 19 (55.9%) patients received maximal androgen block-
age (MAB). Three patients demonstrated PSA progression 
over 0.4 ng/mL. Among them, 1 patient received MAB and 
2 patients received AA monotherapy. Among the HT group, 
4 patients died from non-prostate cancer causes during fol-
low-up (Table 5).  
  
Overall survival of incidental prostate cancer patients
Among 156 patients, a total of 6 (3.8%) patients died dur-
ing follow-up. One patient on AS died due to cerebral hem-
orrhage, while another on WW died due to pancreatic ma-
lignancy. Among the remaining 4 patients on HT, 2 patients 
died due to aging, 1 patient due to liver malignancy and an-
other due to congestive heart failure. During follow-up, no 
patients died due to prostate cancer.
DISCUSSION
Recent studies have shown that the rate of incidental pros-
tate cancer discovery has decreased in the PSA era. Jones, 
et al.8 reported that the incidence of incidental prostate can-
cer has significantly decreased in comparison to the rate 
from the pre-PSA era. They also reported that the most sig-
nificant drop was in cases of clinical stage T1b. Andrèn, et 
al.9 reported similar results in a large Swedish national study 
cohort. Notably, the Swedish study also reported differenc-
es in prostate-cancer-specific mortality. They reported that a 
significant proportion of men diagnosed with incidental 
prostate cancer during the last three decades died from their 
disease; however, prostate-cancer-specific mortality has de-
creased over time in the PSA era. 
In fact, PSA screening has led to an increase in the diag-
nosis of prostate cancer by prostate biopsy. Consequently, a 
large proportion of prostate cancers are being diagnosed in 
Table 4. Pathologic Outcomes of Patients Who Underwent 
Radical Prostatectomy
No. of patients 67
Pathologic stage (%)
    pT0 21 (31.3)
    pT2 40 (58.7)
    pT3   6 (9.0)
Postoperative Gleason score (%) 
    No residual tumor 21 (31.3)
    <6 36 (53.7)
    7   7 (10.5)
    8-10   3 (4.5)
Extracapsular extension (%)   5 (7.5)
Seminal vesicle invasion (%)   1 (1.5)
Perineular invasion (%)   7 (10.5)
Lymphovascular invasion (%)   2 (3.0)
Tumor volume (range) 0.42±0.91 (0-5.6)
Positive surgical margin (%)   8 (11.9)
Insignificant cancer (%)* 50 (74.6)
    cT1a 30
    cT1b 20
Unfavorable disease (%)†   8 (11.9)
    cT1a   3
    cT1b   5
Biochemical recurrence (%)   2 (3.0)
Death during follow-up (%)   0 (0.0)
*Tumor volume <0.5 cm3, organ-confined Gleason ≤6 disease.
†Extracapsular extension and/or seminal vesicle invasion and/or postop-
erative Gleason score ≥8.
Table 5. Clinical Outcomes of Patients Who Received Hor-
mone Therapy
No. of patients 34
Treatment type (%)
    LH-RH agonist   9 (26.5)
    AA monotherapy   6 (17.6)
    MAB 19 (55.9)
PSA progression (%)*   3 (8.8)
    cT1a   2
    cT1b   1
Death during follow-up (%)   4 (11.8)
LH-RH, luteinizing hormone-releasing hormone; AA, anti-androgen; MAB, 
maximal androgen blockage; PSA, prostate-specific antigen.
*PSA progression defined as an increase of  PSA level ≥0.4 ng/mL.
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al.6 reported that a sub-classification of incidental prostate 
cancer was not an independent predictor of biochemical re-
currence after adjustment for PSA, Gleason score, or year 
of surgery in patients who underwent RP. Capitanio, et 
al.7,16 concluded that PSA value before and after surgery 
and Gleason score at surgery were the only significant pre-
dictors of residual cancer after RP. Other studies have 
shown that the current T staging system cannot be used for 
accurate staging of the remnant prostate after TURP, and 
that clinical stage T1a/T1b based on the percentage of the 
resected tumor volume does not represent the status of dis-
ease progression.17 In the present study, we found no signif-
icant evidence on RP specimens to prove that clinical stage 
T1b patients had a worse prognosis than T1a patients, be-
cause our study cohort had a low BCR rate (3.0%). This re-
sult was similar in the HT group. 
In the present study, the rate of insignificant prostate can-
cer, including the absence of residual prostate cancer, was 
higher than that in other published data.7,18 We are at a loss 
to explain why our study cohort had more insignificant pros-
tate cancer in comparison with other studies. Nevertheless, 
considering that the proportion of insignificant prostate can-
cer after RP is unpredictable and that there has been a wide 
variation shown in different studies regardless of clinical 
stage, RP is beginning to be an overtreatment for incidental 
prostate cancer in the PSA era. Accordingly, several authors 
have proposed steps to reduce such overtreatment. Among 
them, Capitanio, et al.19 emphasized the importance of 
communication between urologists and pathologists in inci-
dental prostate cancer management. First, pathologists 
should exam every TURP chip. Second, cancer extent should 
be measured by the percentage of chips infiltrated by cancer. 
They concluded that clinical and pathologic background 
knowledge should be shared for accurate evaluation and 
management.
Recently, Capitanio, et al.1,7,16 concluded that the manage-
ment of incidental prostate cancer should be based on the 
estimated probability of clinical progression compared to 
the relative risk of therapy and survival of the patient. They 
concluded that clinical stage (T1a vs. T1b), Gleason score 
at diagnosis and PSA values before and after TURP are the 
most informative variables in clinical decisions. Rajab, et 
al.20 suggested that the current sub-classification for inci-
dental prostate cancer results in a substantial loss of infor-
mation, and that the sub-classification of incidental prostate 
cancer should be changed from the present two subdivi-
sions to four subdivisions in order to improve prognostic 
and prostate biopsy are frequently performed in patients 
who have a higher PSA level than 4.0 ng/mL. Diagnosis of 
incidental prostate cancer is not made if simultaneous TURP 
and prostate biopsy give a positive result, even if prostate 
cancer is seen in TURP chips. Thus, in the PSA era, inci-
dental prostate cancer can be diagnosed at lower PSA lev-
els. In our study cohort, 91 patients who were tested for 
PSA before TURP had levels less than 4.0 ng/mL, and the 
remaining 65 patients had PSA levels higher than 4.0 ng/
mL. Of these 65 patients, 12 underwent core prostate biop-
sy and were found to have peripheral prostate cancer on bi-
opsy. In other words, these patients were more likely to be 
diagnosed as cancer-free by prostate biopsy if they did not 
undergo TURP. 
Another controversy surrounding incidental prostate can-
cer concerns the choice of clinical staging used to plan pros-
tate cancer treatment. Sub-classification of incidental pros-
tate cancer was based on a study performed 20 years ago. 
Although the characteristics of clinical stage T1a/T1b pa-
tients have gradually changed over the past few decades, 
sub-classifications are still applied without modification. 
The classical approach is to follow T1a patients with an ac-
tive surveillance program and to treat T1b patients. Europe-
an Association of Urology guidelines recommend active 
surveillance for stage T1a and radical prostatectomy for 
stage T1b patients with a life expectancy of more than 10 
years.10 
Descazeaud, et al.11 reported that 30 of 144 (21%) stage 
T1a patients experienced cancer progression during the AS 
period. They concluded that AS was appropriate for these 
patients in the PSA era. In the present study, 12 patients in 
the AS group showed PSA progression. Among these pa-
tients, 6 of 36 (16.7%) stage T1a patients and 6 of 10 (60%) 
stage T1b patients demonstrated PSA progression. Compar-
ing the proportion of those with PSA progression according 
to clinical stage, clinical stage T1b patients seemed to have 
a greater chance of PSA progression in comparison with 
stage T1a patients. However, incidental prostate cancer 
PSA progression is questionable because no consensus def-
inition of progression has been developed. In addition, it is 
unclear whether PSA progression during AS indicates dis-
ease progression in incidental prostate cancer patients. It 
should not be overlooked that, 5 patients in the present study, 
who received RP after PSA progression had organ-confined 
Gleason 6 disease regardless of clinical stage. 
Several studies have reported that stage T1b cancer has a 
poorer prognosis than stage T1a.12-15 However, Magheli, et 
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evaluation. Based on our own experiences, we agree strong-
ly with this suggestion. We believe that the concept of inci-
dental prostate cancer has changed with the wide use of 
PSA screening. In the PSA era, incidental prostate cancer 
patients should be considered to be low-risk prostate cancer 
patients, and immediate definite therapy should be sublated 
for these patients. Before and post-TURP, PSA values or 
systematic prostate biopsy of the remaining prostate tissue 
should be used for proper decision-making. The use of AS 
for these patients over RP or HT as an initial treatment may 
reduce the occurrence of complications due to treatment. 
The present study had several limitations. First, the fol-
low-up period was short in comparison with other studies. 
Second, this study was simply a review of clinical outcomes 
according to initial treatments. Only a few patients who had 
poorly differentiated incidental prostate cancer were includ-
ed in the study cohort. However, our results are comparable 
with other recent findings, and this article is the first report 
of clinical outcomes according to initial treatments using a 
Korean cohort. Even though it was impossible to compare 
the clinical outcomes according to Gleason score at TURP, 
the decrease of patients with poorly differentiated incidental 
prostate cancer was similar to what has been reported by 
other tertiary hospitals. Despite these limitations, we be-
lieve that our clinical experiences could have implications 
for urologists who are involved in the treatment of inciden-
tal prostate cancer patients. 
In conclusion, the clinical outcomes of incidental prostate 
cancer were satisfactory regardless of the initial treatment 
type. However, according to recent research and guidelines, 
immediate definite therapy should be avoided without a 
careful assessment. We also believe that improved clinical 
staging is needed for these patients.
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